Malignant tumors of the cervix

Cervical Malignancies are invasive lesions developing from precancers over an average time of 10–15 years. They have the same cause (mostly chronic infection with oncogenic HPV associated with insufficient immune response) and therefore the same risk factors: risky sex life (promiscuity - more than 6 sexual partners in a lifetime, early coitarchy, sexually transmitted infections – especially chlamydia and HSV-2, hormonal contraception, high number of children), cellular immunity disorder (immunosuppression, immunoincompetence, HIV), smoking and an irresponsible approach to prevention (irregular examinations at the registering gynecologist and as part of mammographic screening).

 For more information see Precancers in gynecology, Malignant tumors in gynecology.

Invasive cervical cancers are preventable (vaccination against HPV, detection in the precancerous stage) and their diagnosis is subject to extensive screening (cytology, colposcopy).

 For more information see Prevention of gynecological tumors.

Histology

Squamous cell carcinomas are 75%, adenocarcinomas are 25%. Other histological types are rare.

Squamous Carcinoma of Cervix

Incidence

Still high annual incidence of 18.5/100,000 women, informs about the shortcomings and possibilities of improving cervical precancer screening (in countries with good screening 10/100,000).

Diagnosis

Early stages tend to be asymptomatic. Discharge, bleeding, pain or hematuria may be present only in advanced stages. Therefore, early diagnosis is important, which is based on preventive examinations associated with cytological and colposcopic examinations.

 For more information see Prevention of gynecological tumors.

The diagnosis is confirmed by biopsy and subsequent histological examination.

Staging

Staging is according to the TNM classification or according to the FIGO classification:

• T1, FIGO I - the tumor affects only the cervix:
  • 1a – microscopic tumor:
    • 1a1 – less than or equal to 3 mm,
    • 1a2 – 3–5 mm.
  • 1b – macroscopic tumor:
    • 1b1 – < 4 cm,
    • 1b2 – > 4 cm.
• T2, FIGO II - the tumor extends outside the uterus:
  • 2a – on the vaginal vaults,
  • 2b – parametrium.
• T3, FIGO III – the tumor affects the pelvic wall or lower 1/3 vagina or causes hydronephrosis:
  • 3a – lower third of the vagina,
  • 3b – pelvic wall or hydronephrosis.
• T4, FIGO IVA - the tumor affects the bladder or rectum or extends beyond the pelvis.

Treatment

 For more information see Surgical treatment of gynecological malignancies, Non-surgical treatment of gynecological malignancies.

It varies by clinical stage. In the early stages, the treatment is surgical, in advanced radiotherapy. If the tumor is less than 5 mm, a simple hysterectomy or fertility-preserving conization is indicated. If the tumor is larger than 5 mm, but only in the cervix, radical hysterectomy according to Wertheim with pelvic lymphadenectomy or fertility-preserving conization or (radical) trachelectomy is indicated, if these procedures affect the entire tumor. If the tumor extends beyond the throat, radiotherapy is indicated (brachytherapy with a uterovaginal applicator ¹³⁷Cs or ¹⁹²Ir with an afterloading system and teleradiotherapy from a linear accelerator or betatron 50 Gy at a dose of 2 Gy /day with possible low doses of cis-platinum as concomitant chemoradiotherapy).

Links

Related Articles

• Cervical tumors
• Malignant tumors in gynecology
• Cervical precancers
• Prevention of gynecological tumors

External links

• www.onkogyn.cz (e.g. the current TNM classification, it is the website of the VFN Oncogynecological Center)
• Human papillomavirus, Mefanet